|For Immediate Release:|
December 5, 2013
Phone: (571) 483-1379
ALEXANDRIA, Va. – The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) today announced the recipients of its 2014 Conquer Cancer Foundation of ASCO Merit Awards in Genitourinary Cancers, which recognize rising oncology researchers for their contributions to the field. The recipients will be recognized at the 2014 Genitourinary Cancers Symposium taking place January 30 – February 1 in San Francisco, CA.
“Young investigators, like those receiving this year’s Merit Awards, are the future of oncology,” said W. Charles Penley, MD, FASCO, Chair of the Conquer Cancer Foundation Board of Directors. “The Conquer Cancer Foundation recognizes their dedication to advancing the care of patients living with cancer and values their efforts toward creating a world free from the fear of cancer.”
This year’s Symposium will feature research advances on the treatment and management of a variety of genitourinary cancers, including cancers of the bladder, kidneys, penis, prostate, testis and urethra. The Conquer Cancer Foundation of ASCO Merit Awards are designed to promote clinical cancer research in these areas by providing the opportunity for recipients to present their findings at the Symposium.
The 2014 Merit Award in Genitourinary Cancers recipients and their abstracts are:
- Arun Azad, MBBS, FRACP, PhD, British Columbia Cancer Agency
Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
- Alejandro Berlin, MD, Princess Margaret Cancer Centre/University Health Network, University of Toronto
Using ΝΒΝ to predict biochemical relapse following image-guided radiotherapy for intermediate-risk prostate cancer.
- Mauricio Burotto Pichun, MD, National Cancer Institute, National Institutes of Health
Phase II clinical trial of bevacizumab plus ixabepilone in renal cell carcinoma.
- Heather Cheng, MD, PhD, University of Washington
The effect of prior abiraterone use on the activity of enzalutamide in men with mCRPC.
- David Chism, MD, MS, UNC Lineberger Comprehensive Cancer Center
BASE47 gene set predictor as an identifier of “basal-like” subtype of urothelial carcinoma of the bladder in African Americans.
- André Fay, MD, Dana-Farber Cancer Institute
PD-L1 expression in non-clear cell renal cell carcinoma.
- Phillip Gray, MD, Harvard Radiation Oncology Program
Modern patterns of care in testicular seminoma: Results from the National Cancer database.
- Abraham Hakimi, MD, Memorial Sloan-Kettering Cancer Center
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
- Jenny Ko, MD, British Columbia Cancer Agency
The international metastatic renal cell carcinoma database consortium model as a prognostic tool in metastatic renal cell carcinoma patients previously treated with first-line targeted therapy.
- Raya Leibowitz-Amit, MD, PhD, Princess Margaret Cancer Centre, University Health Network, University of Toronto
A single-arm, phase II, multicenter trial of sunitinib maleate in locally advanced or metastatic pheochromocytoma/paraganglioma: Interim results.
- Amitkumar Mehta, MD, University of Alabama at Birmingham
Comprehensive kinase profiling to classify clear cell-renal cell carcinoma.
- Christos Mikropoulos, MD, The Royal Marsden Hospital
The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening.
- Matthew Mossanen, MD, University of Washington School of Medicine
Prevalence and adverse impact of extended antibiotic prophylaxis in urologic oncology surgery.
- Matteo Santoni, MD, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria
Differences in terms of progression-free survival and overall survival in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.
- Francisco Vera-Badillo, MD, Princess Margaret Cancer Centre, University Health Network, University of Toronto
Response to systemic therapy in non-clear cell renal cell carcinomas: A systematic review and meta-analysis.
The Conquer Cancer Foundation celebrated the 30th anniversary of its Grants and Awards Program this year. Learn more about this milestone and how you can join the Foundation’s efforts to support the next 30 years at www.conquercancerfoundation.org.
The 2014 Genitourinary Cancers Symposium Merit Awards are supported by: the Conquer Cancer Foundation Mission Endowment; Lilly; Millennium: The Takeda Oncology Company; and Shine for Scott, Inc.